KRAS and cancer: While treatment with DPI alone at 1 μM for 24 h only induced death in 11% of HCT116+/+ cells and 11.9% of HCT116−/− cells (Fig. 3d), the combination with 100 μM BSO induced dramatic cell death in 55.10% of HCT116+/+ cells and 76.30% of HCT116−/− cells (Fig. 3e), demonstrating the effectiveness of the combination treatment in killing cancer cells bearing oncogenic KRAS and p53 mutations.